
Press Release

April 30, 2025

Sumitomo Pharma Co., Ltd.

Sumitomo Pharma Announces Organizational Realignment and Personnel Changes

Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Toru Kimura) today announced the following organizational realignment and personnel changes, effective May 1, 2025.

I. Organizational Realignment (effective May 1, 2025)

Corporate Department

Regenerative Medicine Office is renamed to Regenerative and Cellular Medicine Office.

II. Changes in Personnel (effective May 1, 2025)

Corporate Department

| Position as of May 1, 2025 | Current position | Name |
|--|---|------------------|
| Representative Director, President and CEO, RACTHERA Co., Ltd. Corporate Officer, Regenerative and Cellular Medicine Office | Representative Director, President and CEO, RACTHERA Co., Ltd. Corporate Officer, Regenerative Medicine Office | Atsushi Ikeda |
| Representative Director, President and CEO, S-RACMO Co., Ltd. Corporate Officer, Regenerative and Cellular Medicine Collaboration | Representative Director, President and CEO, S-RACMO Co., Ltd. Corporate Officer, Regenerative Medicine Collaboration | Atsushi Tsuchida |
| Senior Medical Officer, Ophthalmology RACTHERA Co., Ltd. Regenerative and Cellular Medicine Office | Senior Medical Officer, Ophthalmology RACTHERA Co., Ltd. Regenerative Medicine Office | Koichiro Manabe |
| Vice President, RACTHERA Co., Ltd. Vice President, Head of Regenerative and Cellular Medicine Office | Vice President, RACTHERA Co., Ltd. Vice President, Head of Regenerative Medicine Office | Kenji Yoshida |

Contact:

Corporate Communications, Corporate Governance

Sumitomo Pharma Co., Ltd.

E-mail: prir@sumitomo-pharma.co.jp